Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis.
Open Access
- 1 June 1995
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 95 (6) , 2868-2876
- https://doi.org/10.1172/jci117993
Abstract
In the enclosed study we have examined the expression and contribution of specific chemokines, macrophage inflammatory protein 1 alpha (MIP-1 alpha) and macrophage inflammatory protein 2 (MIP-2), and interleukin 10 (IL-10) during the evolution of type II collagen-induced arthritis (CIA). Detectable levels of chemotactic cytokine protein for MIP-1 alpha and MIP-2 were first observed between days 32 and 36, after initial type II collagen challenge, while increases in IL-10 were found between days 36 and 44. CIA mice passively immunized with antibodies directed against either MIP-1 alpha or MIP-2 demonstrated a delay in the onset of arthritis and a reduction of the severity of arthritis. On the contrary, CIA mice receiving neutralizing anti-IL-10 antibodies demonstrated an acceleration of the onset and an increase in the severity of arthritis. Interestingly, anti-IL-10 treatment increased the expression of MIP-1 alpha and MIP-2, as well as increased myeloperoxidase (MPO) activity and leukocyte infiltration in the inflamed joints. These data suggest that MIP-1 alpha and MIP-2 play a crucial role in the initiation and maintenance, while IL-10 appears to play a regulatory role during the development of experimental arthritis.Keywords
This publication has 55 references indexed in Scilit:
- Regulation of neutrophil-derived chemokine expression by IL-10.The Journal of Immunology, 1994
- Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.Journal of Clinical Investigation, 1994
- Interleukin-10 production during septicaemiaThe Lancet, 1994
- Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.1994
- Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.The Journal of Experimental Medicine, 1994
- Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.The Journal of Immunology, 1993
- Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide.The Journal of Experimental Medicine, 1993
- Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.1992
- Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant miceClinical Immunology and Immunopathology, 1992
- Interleukin 1 mediated acceleration of type II collagen-induced arthritis: Effects of anti-inflammatory or anti-arthritic drugsInflammation Research, 1991